Henning Steinhagen, PhD, MBA

CEO and Co-Founder

Dr. Steinhagen joined Epidarex in 2019. He recently co-founded Epidarex Exeed Ltd. and acts as CEO as well as on the Board of Directors. He is a senior executive with 20 years of experience and track record in the Pharma, Biotech and CRO/CDMO industries. Prior to joining Epidarex, Dr. Steinhagen served as President of Research and Development at Aptuit, a leading R&D organization. As an operational leader he led significant growth and transformation of the integrated ex-GSK site in Verona, Italy into a profitable organization. He was a key player in the $300 million private equity sale of Aptuit to Evotec in 2017.

Prior to Aptuit, Dr. Steinhagen acted as Senior Vice President and Head of Global Drug Discovery at Grünenthal in Germany. His accomplishments include the build-up of the immuno-inflammation area as well as advancing Grünenthal’s CNS portfolio, including executing several R&D partnerships and licensing deals. Before joining Grünenthal, Dr. Steinhagen served as a Director of Medicinal Chemistry at Sanofi-Aventis for several years. He started his career at Bayer Pharma and his overall experience spans multiple therapeutic areas and all phases of research and early development.

Dr. Steinhagen has developed strong business acumen through P&L oversight, successful M&A and Biotech licensing and fundraising. In 2018 he completed a global executive MBA program at the IMD in Lausanne, Switzerland.

Apart from Epidarex Exeed Ltd. Dr. Steinhagen also serves on the Board of Directors of Caldan Therapeutics Ltd. as well as senior advisor for several organizations including the Osthus Group and Max-Planck Innovation. He is a member and former chair of the board of MedLife, a not-for-profit MedTech association.

Dr. Steinhagen holds a Ph.D. in Chemistry from the University of Heidelberg with a degree in Molecular Genetics. His academic experiences include a post-doctoral stay with Nobel laureate Prof. E.J. Corey at Harvard University as well as an Adjunct Professorship at Trinity College Dublin, Ireland.